SCHEMBL4011604

SCHEMBL4011604

COc1ccccc1CCc1cc(N)n[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.52
TAAR1 Q96RJ0 1/20 0.50
SIGMAR1 Q99720 1/20 0.45
AOC3 Q16853 1/20 0.45
KCNH2 Q12809 1/20 0.44
DHFR P00374 1/20 0.43
IDO1 P14902 2/20 0.42
ABCB1 P08183 2/20 0.42
GAA P10253 2/20 0.42
KDM1A O60341 1/20 0.42
RCOR1 Q9UKL0 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA5A P35218 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
DYRK1A Q13627 1/20 0.41
AR P10275 1/20 0.41
NR3C2 P08235 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4017701 0.81 HTR1A (0.57) DHFRABCB1
SCHEMBL28782134 0.78 DYRK1A (0.38) HSD17B10DHFRDYRK1AALDH1A1MAPT
SCHEMBL27787986 0.77 TAAR1 (0.50) HSD17B10TAAR1SIGMAR1AOC3KCNH2
SCHEMBL3946519 0.77 CYP19A1 (0.58) HSD17B10AOC3GAACA12CA1
SCHEMBL27773542 0.76 HSD17B10 (0.37) HSD17B10GAADYRK1A
SCHEMBL27752605 0.76 DYRK1A (0.45) HSD17B10GAADYRK1AALDH1A1MAPT
SCHEMBL28858018 0.75 TAAR1 (0.75) TAAR1SIGMAR1AOC3KCNH2IDO1
SCHEMBL20802046 0.73 FGFR4 (0.46) HSD17B10GAADYRK1AALDH1A1MAPT
SCHEMBL4016450 0.73 DYRK1A (0.58) TAAR1SIGMAR1AOC3DYRK1AALDH1A1
SCHEMBL3947733 0.73 COMT (0.49) TAAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101501030-A Pyrimidine derivatives useful in the treatment of cancer ASTRAZENECA AB (SE) 2009-08-05 CN disclosed
EP-2044063-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Astra Zeneca AB (SE) 2009-04-08 EP disclosed
WO-2008001070-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-01-03 WO disclosed
US-20080004302-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004302-A1 Novel Compounds CYP11B2, CYP11B1, CYP46A1 HSD17B10 157/4885TAAR1 3903/4885SIGMAR1 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.